WallStSmart

Arm Holdings plc American Depositary Shares (ARM)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 900% more annual revenue ($46.72B vs $4.67B). ARM leads profitability with a 17.2% profit margin vs 16.7%. ARM appears more attractively valued with a PEG of 1.90. ARM earns a higher WallStSmart Score of 52/100 (C-).

ARM

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 7.0Value: 4.7Quality: 7.8
Piotroski: 5/9Altman Z: 3.75

SNY

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 6.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ARMSignificantly Overvalued (-2323.2%)

Margin of Safety

-2323.2%

Fair Value

$5.17

Current Price

$157.07

$151.90 premium

UndervaluedFair: $5.17Overvalued
SNYSignificantly Overvalued (-89.7%)

Margin of Safety

-89.7%

Fair Value

$24.79

Current Price

$46.03

$21.24 premium

UndervaluedFair: $24.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARM3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
3.7510/10

Safe zone — low bankruptcy risk

Market CapQuality
$143.33B9/10

Large-cap with strong market position

Revenue GrowthGrowth
26.3%8/10

Revenue surging 26.3% year-over-year

SNY3 strengths · Avg: 9.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Market CapQuality
$109.03B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.59B8/10

Generating 1.6B in free cash flow

Areas to Watch

ARM4 concerns · Avg: 2.5/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

P/E RatioValuation
177.6x2/10

Premium valuation, high expectations priced in

Price/BookValuation
21.4x2/10

Trading at 21.4x book value

EPS GrowthGrowth
-12.3%2/10

Earnings declined 12.3%

SNY3 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.4%4/10

2.4% earnings growth

Return on EquityProfitability
6.7%3/10

ROE of 6.7% — below average capital efficiency

PEG RatioValuation
4.322/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ARM

The strongest argument for ARM centers on Altman Z-Score, Market Cap, Revenue Growth. Profitability is solid with margins at 17.2% and operating margin at 15.4%. Revenue growth of 26.3% demonstrates continued momentum.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.7% and operating margin at 14.3%.

Bear Case : ARM

The primary concerns for ARM are PEG Ratio, P/E Ratio, Price/Book. A P/E of 177.6x leaves little room for execution misses.

Bear Case : SNY

The primary concerns for SNY are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

ARM profiles as a growth stock while SNY is a mature play — different risk/reward profiles.

ARM carries more volatility with a beta of 4.13 — expect wider price swings.

ARM is growing revenue faster at 26.3% — sustainability is the question.

SNY generates stronger free cash flow (1.6B), providing more financial flexibility.

Bottom Line

ARM scores higher overall (52/100 vs 49/100), backed by strong 17.2% margins and 26.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arm Holdings plc American Depositary Shares

TECHNOLOGY · SEMICONDUCTORS · USA

Arm Holdings plc architects, develops, and licenses central processing unit products and related technologies for semiconductor companies and original equipment manufacturers rely on to develop products.

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?